“2020 will be remembered as the year of the biotech sector,” declares the author of today’s article, who proceeds to highlight two biotech stocks that Morgan Stanley is bullish on – and which have also earned “Strong Buy” consensus ratings from the analyst community at large. For these two biotech stocks with significant upside potential, CLICK HERE.
These 2 Small-Cap Biotech And Pharma Stocks Boast “Strong Buy” Ratings And Significant Upside Potential
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.
“With some investors now looking to take on a bit more risk, they are turning to the ultimate risk/reward plays: biotech stocks,” notes the author of today’s article. One of the few major catalysts for biotech stocks is regulatory approval – and the author highlights “three compelling biotech stocks with upcoming Prescription Drug User Fee Act (PDUFA) dates, the deadline…